Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Economic information and modeling reportBudget impact model

Epidemiology and eligible population inputs

9 evidence topics · 6 sources

Budget impact model of cretostimogene grenadenorepvec: eligible population inputs

No evidence found.

Eligible population inputs in a published budget impact model

“In the base-case analysis, the model considered adults (aged ≥18 years) with high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1. Prevalent cases were considered in Year 1 and incident cases were considered in Years 2–3.” (opens the source at this quote in a new tab)

“Specifically, the prevalence of bladder cancer was 0.0634% and the incidence was 0.0244%, based on US Surveillance, Epidemiology, and End Results Program (SEER) registry data” (opens the source at this quote in a new tab)

“a real-world study of treatment patterns and clinical outcomes of US patients with bladder cancer based on the SEER-Medicare claims data, 73.1% of all patients with bladder cancer had NMIBC and, among them, 42.3% were classified as high-risk; 16.5% of patients with high-risk NMIBC had CIS ± Ta/T1 while 83.5% had high-grade Ta/T1 only” (opens the source at this quote in a new tab)

“Among patients with high-risk NMIBC, 56.5% were treated with BCG” (opens the source at this quote in a new tab)

“and 30% of those were unresponsive to BCG” (opens the source at this quote in a new tab)

“Among adults with high-risk, BCG-unresponsive NMIBC, 92.6% and 81.2% remained alive at Years 2 and 3, respectively, based on an analysis of SEER Medicare claims data” (opens the source at this quote in a new tab)

“An annual recurrence rate of 55.1% was used” (opens the source at this quote in a new tab)